Skip to main content

Nkarta, Inc. (NKTX)

NASDAQ: NKTX · IEX Real-Time Price · USD
15.97
0.49 (3.17%)
At close: Dec 8, 2021 4:00 PM
16.00
0.03 (0.19%)
After-hours:Dec 8, 2021 7:40 PM EST
Market Cap526.20M
Revenue (ttm)n/a
Net Income (ttm)-81.16M
Shares Out32.95M
EPS (ttm)-2.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume189,374
Open15.50
Previous Close15.48
Day's Range15.06 - 16.20
52-Week Range13.05 - 79.16
Betan/a
AnalystsStrong Buy
Price Target69.67 (+336.3%)
Earnings DateNov 11, 2021

About NKTX

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic synd...

IndustryBiotechnology
IPO DateJul 10, 2020
Employees133
Stock ExchangeNASDAQ
Ticker SymbolNKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for Nkarta stock is "Strong Buy." The 12-month stock price forecast is 69.67, which is an increase of 336.26% from the latest price.

Price Target
$69.67
(336.26% upside)
Analyst Consensus: Strong Buy

News

Can Nkarta (NKTX) Climb 270% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Nkarta (NKTX) points to a 270.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...

3 weeks ago - Zacks Investment Research

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an...

3 weeks ago - GlobeNewsWire

Nkarta Reports Third Quarter 2021 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today re...

4 weeks ago - GlobeNewsWire

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an...

1 month ago - GlobeNewsWire

Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022

Nkarta Inc (NASDAQ: NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes. Data from the...

2 months ago - Benzinga

Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an...

2 months ago - GlobeNewsWire

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an...

2 months ago - GlobeNewsWire

Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today a...

2 months ago - GlobeNewsWire

Nkarta Reports Second Quarter 2021 Financial Results and Business Progress

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today re...

3 months ago - GlobeNewsWire

Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site

Nkarta Therapeutics Inc (NASDAQ: NKTX) will be moving into an 88,000-square-foot facility that will not only serve as its newest headquarters but will support the research, development, and future comme...

4 months ago - Benzinga

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an...

4 months ago - GlobeNewsWire

Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an...

5 months ago - GlobeNewsWire

How Much Will the Nkarta Deal Help CRISPR Therapeutics?

Unfortunately, this isn't an endorsement by a big drug developer.

Other symbols:CRSP
6 months ago - The Motley Fool

Nkarta Announces June 2021 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today ann...

6 months ago - GlobeNewsWire

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today rep...

6 months ago - GlobeNewsWire

Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer

Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all th...

Other symbols:CRSP
7 months ago - Benzinga

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Ce...

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today a...

7 months ago - GlobeNewsWire

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ...

8 months ago - GlobeNewsWire

Nkarta Announces February and March 2021 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

9 months ago - GlobeNewsWire

Biotech Shares Have Soared Since 2020's Wave of IPOs

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Other symbols:AVIRJNJLEGNLLYRNA
9 months ago - GuruFocus

Nkarta Reports Third Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

1 year ago - GlobeNewsWire

Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer...

First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D

1 year ago - GlobeNewsWire

Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at ...

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

1 year ago - GlobeNewsWire

Nkarta Announces November & December 2020 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

1 year ago - GlobeNewsWire

Nkarta Announces Leadership Changes

Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager , J.D., Ph.D. to Join as Chief Legal Officer

1 year ago - GlobeNewsWire